{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:32:44Z","timestamp":1794411164081,"version":"4.9.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013105","name":"Shanghai Rising-Star Program","doi-asserted-by":"publisher","award":["21QA1409000"],"award-info":[{"award-number":["21QA1409000"]}],"id":[{"id":"10.13039\/501100013105","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.biopha.2022.113127","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T08:48:52Z","timestamp":1653036532000},"page":"113127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease"],"prefix":"10.1016","volume":"151","author":[{"given":"Jiashu","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianjun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113127_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113127_bib2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113127_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010015","article-title":"Nonalcoholic fatty liver disease: a challenge from mechanisms to therapy","volume":"9","author":"Tarantino","year":"2019","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.biopha.2022.113127_bib4","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2022.113127_bib5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.biopha.2022.113127_bib6","doi-asserted-by":"crossref","first-page":"20704","DOI":"10.3390\/ijms141020704","article-title":"Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)","volume":"14","author":"Takaki","year":"2013","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113127_bib7","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113127_bib8","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113127_bib9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.21037\/hbsn.2019.05.08","article-title":"Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed?","volume":"8","author":"Kim","year":"2019","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.biopha.2022.113127_bib10","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2022.113127_bib11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pharmthera.2017.05.011","article-title":"Targeting nuclear receptors for the treatment of fatty liver disease","volume":"179","author":"Tanaka","year":"2017","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113127_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052668","article-title":"Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease","volume":"23","author":"Puengel","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113127_bib13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/fca.10.86","article-title":"Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease","volume":"6","author":"Azhar","year":"2010","journal-title":"Future Cardiol."},{"key":"10.1016\/j.biopha.2022.113127_bib14","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00018-018-2838-4","article-title":"Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation","volume":"75","author":"Silva","year":"2018","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.biopha.2022.113127_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nm1025","article-title":"PPARs and the complex journey to obesity","volume":"10","author":"Evans","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.113127_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nature07202","article-title":"Integration of metabolism and inflammation by lipid-activated nuclear receptors","volume":"454","author":"Bensinger","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113127_bib17","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113127_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113127_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.apsb.2019.11.017","article-title":"Herbal drug discovery for the treatment of nonalcoholic fatty liver disease","volume":"10","author":"Yan","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2022.113127_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/549627","article-title":"Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases","volume":"2013","author":"Monsalve","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.biopha.2022.113127_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071638","article-title":"Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease","volume":"9","author":"Fougerat","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2022.113127_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.biochi.2004.11.009","article-title":"Regulatory role of peroxisome proliferator-activated receptor delta (PPAR delta) in muscle metabolism. A new target for metabolic syndrome treatment?","volume":"87","author":"Grimaldi","year":"2005","journal-title":"Biochimie"},{"key":"10.1016\/j.biopha.2022.113127_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2022.113127_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111255","article-title":"Crosstalk between PPARs and gut microbiota in NAFLD","volume":"136","author":"Wu","year":"2021","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2022.113127_bib25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2022.113127_bib26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endo.137.1.8536636","article-title":"Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat","volume":"137","author":"Braissant","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2022.113127_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113127_bib28","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2022.113127_bib29","doi-asserted-by":"crossref","first-page":"28918","DOI":"10.1074\/jbc.M910350199","article-title":"Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting","volume":"275","author":"Hashimoto","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113127_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/ATVBAHA.107.148817","article-title":"Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?","volume":"28","author":"Barter","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2022.113127_bib31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s11745-016-4160-y","article-title":"Free fatty acids increase intracellular lipid accumulation and oxidative stress by modulating PPAR\u03b1 and SREBP-1c in L-02 cells","volume":"51","author":"Qin","year":"2016","journal-title":"Lipids"},{"key":"10.1016\/j.biopha.2022.113127_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biochi.2017.07.003","article-title":"Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice","volume":"140","author":"Veiga","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.biopha.2022.113127_bib33","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/hep.27297","article-title":"The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice","volume":"60","author":"Pawlak","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113127_bib34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbrc.2004.09.110","article-title":"PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats","volume":"324","author":"Toyama","year":"2004","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2022.113127_bib35","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113127_bib36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tips.2019.12.005","article-title":"Targeting FGF21 for the treatment of nonalcoholic steatohepatitis","volume":"41","author":"Zarei","year":"2020","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.biopha.2022.113127_bib37","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jcmgh.2021.01.012","article-title":"Transcriptional regulation of metabolic pathways via lipid-sensing nuclear receptors PPARs, FXR, and LXR in NASH","volume":"11","author":"Cariello","year":"2021","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113127_bib38","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbrc.2008.04.086","article-title":"Quantitative expression patterns of peroxisome proliferator-activated receptor-beta\/delta (PPARbeta\/delta) protein in mice","volume":"371","author":"Girroir","year":"2008","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2022.113127_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030913","article-title":"PPAR\u03b2\/\u03b4: a key therapeutic target in metabolic disorders","volume":"19","author":"Palomer","year":"2018","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113127_bib40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","article-title":"Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity","volume":"113","author":"Wang","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.113127_bib41","doi-asserted-by":"crossref","first-page":"15924","DOI":"10.1073\/pnas.0306981100","article-title":"Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome","volume":"100","author":"Tanaka","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.113127_bib42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41419-019-1458-8","article-title":"PPAR\u03b4 attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation","volume":"10","author":"Tong","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2022.113127_bib43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cca.2020.05.042","article-title":"Emerging role of Insig-1 in lipid metabolism and lipid disorders","volume":"508","author":"Ouyang","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.biopha.2022.113127_bib44","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/hep.22334","article-title":"Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice","volume":"48","author":"Qin","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113127_bib45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molmet.2017.12.008","article-title":"Hepatic regulation of VLDL receptor by PPAR\u03b2\/\u03b4 and FGF21 modulates non-alcoholic fatty liver disease","volume":"8","author":"Zarei","year":"2018","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2022.113127_bib46","doi-asserted-by":"crossref","first-page":"20874","DOI":"10.1074\/jbc.M312802200","article-title":"Peroxisome proliferator-activated receptor beta\/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet","volume":"279","author":"Akiyama","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113127_bib47","article-title":"Insights into the role of PPAR\u03b2\/\u03b4 in NAFLD","volume":"19","author":"Chen","year":"2018","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113127_bib48","doi-asserted-by":"crossref","first-page":"25448","DOI":"10.1074\/jbc.M301189200","article-title":"Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells","volume":"278","author":"Hoekstra","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113127_bib49","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cmet.2008.04.003","article-title":"Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance","volume":"7","author":"Odegaard","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2022.113127_bib50","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cmet.2008.04.002","article-title":"Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity","volume":"7","author":"Kang","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2022.113127_bib51","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J. Mol. Med (Berl. )"},{"key":"10.1016\/j.biopha.2022.113127_bib52","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113127_bib53","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.3748\/wjg.v21.i45.12787","article-title":"Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease","volume":"21","author":"Lee","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2022.113127_bib54","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3748\/wjg.14.22","article-title":"Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease","volume":"14","author":"Kallwitz","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2022.113127_bib55","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/gt.2010.41","article-title":"PPARgamma is essential for protection against nonalcoholic steatohepatitis","volume":"17","author":"Wu","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.biopha.2022.113127_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/JOE-16-0447","article-title":"Hepatocyte-specific, PPAR\u03b3-regulated mechanisms to promote steatosis in adult mice","volume":"232","author":"Wolf Greenstein","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.biopha.2022.113127_bib57","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bcpt.13190","article-title":"A role of peroxisome proliferator-activated receptor \u03b3 in non-alcoholic fatty liver disease","volume":"124","author":"Skat-R\u00f8rdam","year":"2019","journal-title":"Basic Clin. Pharm. Toxicol."},{"key":"10.1016\/j.biopha.2022.113127_bib58","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bbalip.2017.12.002","article-title":"Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins","volume":"1863","author":"Zhang","year":"2018","journal-title":"Biochim Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.biopha.2022.113127_bib59","article-title":"Peroxisome proliferator-activated receptor-gamma reduces ER stress and inflammation via targeting NGBR expression","volume":"12","author":"Ma","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2022.113127_bib60","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1111\/jgh.15025","article-title":"Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4\/NF-\u03baB signaling pathway","volume":"35","author":"Wu","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113127_bib61","doi-asserted-by":"crossref","first-page":"44612","DOI":"10.1038\/srep44612","article-title":"Effect of modulation of PPAR-\u03b3 activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113127_bib62","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113127_bib63","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.biocel.2010.02.006","article-title":"Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro","volume":"42","author":"Yu","year":"2010","journal-title":"Int J. Biochem Cell Biol."},{"key":"10.1016\/j.biopha.2022.113127_bib64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0168-8278(99)80010-5","article-title":"The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo","volume":"30","author":"Hellerbrand","year":"1999","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113127_bib65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13105-020-00777-7","article-title":"Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-\u03b21\/Smad signaling pathway","volume":"77","author":"Ni","year":"2021","journal-title":"J. Physiol. Biochem"},{"key":"10.1016\/j.biopha.2022.113127_bib66","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3233\/CBM-170157","article-title":"Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study","volume":"20","author":"Deng","year":"2017","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.biopha.2022.113127_bib67","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.biopha.2017.04.125","article-title":"Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPAR\u03b1\/AdipoR2, in vivo and in vitro","volume":"91","author":"Chen","year":"2017","journal-title":"Biomed. Pharmacother. = Biomedecine Pharmacother."},{"key":"10.1016\/j.biopha.2022.113127_bib68","first-page":"401","article-title":"Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor \u03b1","volume":"19","author":"Cui","year":"2021","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.biopha.2022.113127_bib69","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1007\/s00018-010-0454-z","article-title":"AMP-activated protein kinase and its downstream transcriptional pathways","volume":"67","author":"Cant\u00f3","year":"2010","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.biopha.2022.113127_bib70","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3892\/ijmm.2015.2074","article-title":"Puerarin ameliorates hepatic steatosis by activating the PPAR\u03b1 and AMPK signaling pathways in hepatocytes","volume":"35","author":"Kang","year":"2015","journal-title":"Int J. Mol. Med"},{"key":"10.1016\/j.biopha.2022.113127_bib71","first-page":"1","article-title":"Salidroside inhibits insulin resistance and hepatic steatosis by downregulating miR-21 and subsequent activation of AMPK and upregulation of PPAR\u03b1 in the liver and muscles of high fat diet-fed rats","author":"Almohawes","year":"2022","journal-title":"Arch. Physiol. Biochem"},{"key":"10.1016\/j.biopha.2022.113127_bib72","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1139\/apnm-2019-0057","article-title":"Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPAR\u03b1 pathway","volume":"45","author":"Huang","year":"2020","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"10.1016\/j.biopha.2022.113127_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12010055","article-title":"Lentinan protects against nonalcoholic fatty liver disease by reducing oxidative stress and apoptosis via the PPAR\u03b1 pathway","volume":"12","author":"Du","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.biopha.2022.113127_bib74","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1055\/a-0895-5838","article-title":"Preventive effects of total flavonoid c-glycosides from abrus mollis on nonalcoholic fatty liver disease through activating the PPAR\u03b1 signaling pathway","volume":"85","author":"Hu","year":"2019","journal-title":"Planta Med"},{"key":"10.1016\/j.biopha.2022.113127_bib75","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/mnfr.201500689","article-title":"Biochanin A improves hepatic steatosis and insulin resistance by regulating the hepatic lipid and glucose metabolic pathways in diet-induced obese mice","volume":"60","author":"Park","year":"2016","journal-title":"Mol. Nutr. Food Res"},{"key":"10.1016\/j.biopha.2022.113127_bib76","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1128\/MCB.20.5.1868-1876.2000","article-title":"The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes","volume":"20","author":"Vega","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2022.113127_bib77","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/253817","article-title":"The PPARalpha-PGC-1alpha axis controls cardiac energy metabolism in healthy and diseased myocardium","volume":"2008","author":"Duncan","year":"2008","journal-title":"PPAR Res"},{"key":"10.1016\/j.biopha.2022.113127_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153919","article-title":"Seed oil of Rosa roxburghii Tratt against non-alcoholic fatty liver disease in vivo and in vitro through PPAR\u03b1\/PGC-1\u03b1-mediated mitochondrial oxidative metabolism","volume":"98","author":"Ni","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.biopha.2022.113127_bib79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1556\/2060.2020.00001","article-title":"Betanin effect on PPAR-\u03b1 and SREBP-1c expression in NMRI mice model of steatohepatitis with fibrosis","volume":"107","author":"Yahaghi","year":"2020","journal-title":"Physiol. Int"},{"key":"10.1016\/j.biopha.2022.113127_bib80","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1016\/j.bmcl.2011.07.095","article-title":"Ursolic acid is a PPAR-\u03b1 agonist that regulates hepatic lipid metabolism","volume":"21","author":"Jia","year":"2011","journal-title":"Bioorg. Med Chem. Lett."},{"key":"10.1016\/j.biopha.2022.113127_bib81","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.fct.2013.04.018","article-title":"Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH) via modulation of PPAR\u03b1 and SREBP-1","volume":"58","author":"Ziamajidi","year":"2013","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.biopha.2022.113127_bib82","doi-asserted-by":"crossref","first-page":"19288","DOI":"10.1038\/srep19288","article-title":"Dietary component isorhamnetin is a PPAR\u03b3 antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113127_bib83","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1017\/S0007114518000739","article-title":"Soya protein \u03b2-conglycinin ameliorates fatty liver and obesity in diet-induced obese mice through the down-regulation of PPAR\u03b3","volume":"119","author":"Li","year":"2018","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.biopha.2022.113127_bib84","doi-asserted-by":"crossref","first-page":"46735","DOI":"10.1038\/srep46735","article-title":"Synthesis and anti-obesity effects in vivo of Crotadihydrofuran C as a novel PPAR\u03b3 antagonist from Crotalaria albida","volume":"7","author":"Sun","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113127_bib85","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2021.09.059","article-title":"18:0 Lyso PC, a natural product with potential PPAR-\u03b3 agonistic activity, plays hypoglycemic effect with lower liver toxicity and cardiotoxicity in db\/db mice","volume":"579","author":"Ma","year":"2021","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2022.113127_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101412","article-title":"Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: Involvement of reduced PPAR\u03b3 expression","volume":"30","author":"Li","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2022.113127_bib87","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","article-title":"Role of nrf2 in oxidative stress and toxicity","volume":"53","author":"Ma","year":"2013","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"10.1016\/j.biopha.2022.113127_bib88","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/10715762.2017.1422602","article-title":"Scutellarin ameliorates nonalcoholic fatty liver disease through the PPAR\u03b3\/PGC-1\u03b1-Nrf2 pathway","volume":"52","author":"Zhang","year":"2018","journal-title":"Free Radic. Res"},{"key":"10.1016\/j.biopha.2022.113127_bib89","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.intimp.2018.03.036","article-title":"Micheliolide alleviates hepatic steatosis in db\/db mice by inhibiting inflammation and promoting autophagy via PPAR-\u03b3-mediated NF-\u043aB and AMPK\/mTOR signaling","volume":"59","author":"Zhong","year":"2018","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.biopha.2022.113127_bib90","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/mnfr.201300482","article-title":"Daidzein regulates proinflammatory adipokines thereby improving obesity-related inflammation through PPAR\u03b3","volume":"58","author":"Sakamoto","year":"2014","journal-title":"Mol. Nutr. Food Res"},{"key":"10.1016\/j.biopha.2022.113127_bib91","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/509057","article-title":"Genistein attenuates nonalcoholic steatohepatitis and increases hepatic PPAR\u03b3 in a rat model","volume":"2015","author":"Susutlertpanya","year":"2015","journal-title":"Evid. Based Complement Altern. Med"},{"key":"10.1016\/j.biopha.2022.113127_bib92","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bcp.2014.03.016","article-title":"Chrysin attenuates inflammation by regulating M1\/M2 status via activating PPAR\u03b3","volume":"89","author":"Feng","year":"2014","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.biopha.2022.113127_bib93","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/jgh.13853","article-title":"Honokiol attenuates diet-induced non-alcoholic steatohepatitis by regulating macrophage polarization through activating peroxisome proliferator-activated receptor \u03b3","volume":"33","author":"Zhong","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113127_bib94","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1124\/pr.119.017897","article-title":"Brothers in arms: ABCA1- and ABCG1-mediated cholesterol efflux as promising targets in cardiovascular disease treatment","volume":"72","author":"Frambach","year":"2020","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.biopha.2022.113127_bib95","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1021\/acs.jnatprod.1c00881","article-title":"Evodiamine lowers blood lipids by up-regulating the PPAR\u03b3\/ABCG1 pathway in high-fat-diet-fed mice","volume":"84","author":"Hou","year":"2021","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.biopha.2022.113127_bib96","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.orcp.2017.02.002","article-title":"Phillyrin lowers body weight in obese mice via the modulation of PPAR<beta>\/<delta>-ANGPTL 4 pathway","volume":"12","author":"Xiao","year":"2018","journal-title":"Obes. Res Clin. Pr."},{"key":"10.1016\/j.biopha.2022.113127_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23092098","article-title":"Mechanism of action of magnesium lithospermate B against aging and obesity-induced ER Stress, insulin resistance, and inflammsome formation in the liver","volume":"23","author":"Jeong","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2022.113127_bib98","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2012.12.020","article-title":"Ombuin-3-O-\u03b2-D-glucopyranoside from Gynostemma pentaphyllum is a dual agonistic ligand of peroxisome proliferator-activated receptors \u03b1 and \u03b4\/\u03b2","volume":"430","author":"Malek","year":"2013","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2022.113127_bib99","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1271\/bbb.130541","article-title":"\u03b3-Mangostin from Garcinia mangostana pericarps as a dual agonist that activates Both PPAR\u03b1 and PPAR\u03b4","volume":"77","author":"Matsuura","year":"2013","journal-title":"Biosci. Biotechnol. Biochem"},{"key":"10.1016\/j.biopha.2022.113127_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012399","article-title":"Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha","volume":"5","author":"Goldwasser","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.113127_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110155","article-title":"Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR-\u03b3 and PPAR-\u03b1","volume":"127","author":"Xie","year":"2020","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2022.113127_bib102","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2337\/db07-0972","article-title":"Therapeutic potential of peroxisome proliferators--activated receptor-alpha\/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2022.113127_bib103","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3892\/ijmm.2016.2531","article-title":"5,7-Dihydroxy-6-geranylflavanone improves insulin sensitivity through PPAR\u03b1\/\u03b3 dual activation","volume":"37","author":"Lee","year":"2016","journal-title":"Int J. Mol. Med"},{"key":"10.1016\/j.biopha.2022.113127_bib104","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5558731","article-title":"Activation of the peroxisome proliferator-activated receptors (PPAR-\u03b1\/\u03b3) and the fatty acid metabolizing enzyme protein CPT1A by camel milk treatment counteracts the high-fat diet-induced nonalcoholic fatty liver disease","volume":"2021","author":"AlNafea","year":"2021","journal-title":"PPAR Res"},{"key":"10.1016\/j.biopha.2022.113127_bib105","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3109\/13880209.2015.1089295","article-title":"Osthole improves glucose and lipid metabolism via modulation of PPAR\u03b1\/\u03b3-mediated target gene expression in liver, adipose tissue, and skeletal muscle in fatty liver rats","volume":"54","author":"Qi","year":"2016","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.biopha.2022.113127_bib106","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.bbadis.2018.06.023","article-title":"Animal models of NAFLD from a hepatologist\u2019s point of view","volume":"1865","author":"Jahn","year":"2019","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.biopha.2022.113127_bib107","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/advances\/nmaa081","article-title":"Animal models of fibrosis in nonalcoholic steatohepatitis: do they reflect human disease?","volume":"11","author":"Ipsen","year":"2020","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.biopha.2022.113127_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8020028","article-title":"NAFLD preclinical models: more than a handful, less of a concern?","volume":"8","author":"Oligschlaeger","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2022.113127_bib109","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","article-title":"Mouse models of nonalcoholic steatohepatitis in preclinical drug development","volume":"22","author":"Hansen","year":"2017","journal-title":"Drug Disco Today"},{"key":"10.1016\/j.biopha.2022.113127_bib110","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/hep.30333","article-title":"Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis","volume":"69","author":"Farrell","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113127_bib111","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J. Hepatol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222005169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222005169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:46:56Z","timestamp":1787597216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222005169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":111,"alternative-id":["S0753332222005169"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113127","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113127"}}